These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 24112154)

  • 1. Predicting value of serum soluble ST2 and interleukin-33 for risk stratification and prognosis in patients with acute myocardial infarction.
    Zhang K; Zhang XC; Mi YH; Liu J
    Chin Med J (Engl); 2013; 126(19):3628-31. PubMed ID: 24112154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP.
    Dhillon OS; Narayan HK; Quinn PA; Squire IB; Davies JE; Ng LL
    Am Heart J; 2011 Jun; 161(6):1163-70. PubMed ID: 21641364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-discharge risk stratification in unselected STEMI: is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers?
    Dhillon OS; Narayan HK; Khan SQ; Kelly D; Quinn PA; Squire IB; Davies JE; Ng LL
    Int J Cardiol; 2013 Sep; 167(5):2182-8. PubMed ID: 22835988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction.
    Weir RA; Miller AM; Murphy GE; Clements S; Steedman T; Connell JM; McInnes IB; Dargie HJ; McMurray JJ
    J Am Coll Cardiol; 2010 Jan; 55(3):243-50. PubMed ID: 20117403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction.
    Shah KB; Kop WJ; Christenson RH; Diercks DB; Henderson S; Hanson K; Li SY; deFilippi CR
    Clin Chem; 2011 Jun; 57(6):874-82. PubMed ID: 21515743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of Soluble ST2 During Hospitalization for ST-Segment Elevation Myocardial Infarction.
    Barbarash O; Gruzdeva O; Uchasova E; Dyleva Y; Belik E; Akbasheva O; Karetnikova V; Shilov A
    Ann Lab Med; 2016 Jul; 36(4):313-9. PubMed ID: 27139603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of ST2, IL-33 and BNP in predicting major adverse cardiovascular events in acute myocardial infarction after percutaneous coronary intervention.
    Wang YP; Wang JH; Wang XL; Liu JY; Jiang FY; Huang XL; Hang JY; Qin W; Ma SX; Zhang J; Yuan MJ; Li JB; Lu ZG; Wei M
    J Cell Mol Med; 2017 Nov; 21(11):2677-2684. PubMed ID: 28623858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble ST2 is a marker for acute cardiac allograft rejection.
    Pascual-Figal DA; Garrido IP; Blanco R; Minguela A; Lax A; Ordoñez-Llanos J; Bayes-Genis A; Valdés M; Moore SA; Januzzi JL
    Ann Thorac Surg; 2011 Dec; 92(6):2118-24. PubMed ID: 22035779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction.
    Sabatine MS; Morrow DA; Higgins LJ; MacGillivray C; Guo W; Bode C; Rifai N; Cannon CP; Gerszten RE; Lee RT
    Circulation; 2008 Apr; 117(15):1936-44. PubMed ID: 18378613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved early risk stratification of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention using a combination of serum soluble ST2 and NT-proBNP.
    Yu J; Oh PC; Kim M; Moon J; Park YM; Lee K; Suh SY; Han SH; Byun K; Ahn T; Kang WC
    PLoS One; 2017; 12(8):e0182829. PubMed ID: 28796845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study.
    Dieplinger B; Egger M; Haltmayer M; Kleber ME; Scharnagl H; Silbernagel G; de Boer RA; Maerz W; Mueller T
    Clin Chem; 2014 Mar; 60(3):530-40. PubMed ID: 24401186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction.
    Pascual-Figal DA; Ordoñez-Llanos J; Tornel PL; Vázquez R; Puig T; Valdés M; Cinca J; de Luna AB; Bayes-Genis A;
    J Am Coll Cardiol; 2009 Dec; 54(23):2174-9. PubMed ID: 19942089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble ST2 and N-terminal pro-brain natriuretic peptide combination. Useful biomarker for predicting outcome of childhoodpulmonary arterial hypertension.
    Chida A; Sato H; Shintani M; Nakayama T; Kawamura Y; Furutani Y; Inai K; Saji T; Matsuoka R; Nonoyama S; Nakanishi T
    Circ J; 2014; 78(2):436-42. PubMed ID: 24304538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of plasma soluble ST2 in hospitalized Chinese patients with heart failure.
    Zhang R; Zhang Y; Zhang J; An T; Huang Y; Guo X; Januzzi JL; Cappola TP; Yin S; Wang Y; Zhou Q; Zou C; Ji S; Lv R
    PLoS One; 2014; 9(10):e110976. PubMed ID: 25347817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-1 receptor-related protein ST2 and mitral valve repair outcome in patients with chronic degenerative mitral regurgitation.
    Galeone A; Lessana A; Mascolo E; Di Serio F; Marraudino N; Laborde F; Paparella D
    Thorac Cardiovasc Surg; 2014 Feb; 62(1):47-51. PubMed ID: 24065602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Independent and incremental prognostic value of novel cardiac biomarkers in chronic hemodialysis patients.
    Obokata M; Sunaga H; Ishida H; Ito K; Ogawa T; Ando Y; Kurabayashi M; Negishi K
    Am Heart J; 2016 Sep; 179():29-41. PubMed ID: 27595677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure.
    Pascual-Figal DA; Manzano-Fernández S; Boronat M; Casas T; Garrido IP; Bonaque JC; Pastor-Perez F; Valdés M; Januzzi JL
    Eur J Heart Fail; 2011 Jul; 13(7):718-25. PubMed ID: 21551163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality.
    Hughes MF; Appelbaum S; Havulinna AS; Jagodzinski A; Zeller T; Kee F; Blankenberg S; Salomaa V;
    Heart; 2014 Nov; 100(21):1715-21. PubMed ID: 25080471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T.
    Dispenzieri A; Gertz MA; Saenger A; Kumar SK; Lacy MQ; Buadi FK; Dingli D; Leung N; Zeldenrust S; Hayman SR; Kapoor P; Grogan M; Hwa L; Russell SJ; Go RS; Rajkumar SV; Kyle RA; Jaffe A
    Am J Hematol; 2015 Jun; 90(6):524-8. PubMed ID: 25753178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Soluble ST2 as a Prognostic Marker in Patients with Acute Heart Failure and Renal Insufficiency.
    Kim MS; Jeong TD; Han SB; Min WK; Kim JJ
    J Korean Med Sci; 2015 May; 30(5):569-75. PubMed ID: 25931787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.